Meeting UK national targets for lipids in acute coronary syndrome with early and intensive lipid reduction: A single centre District general hospital experience

British Journal of Diabetes and Vascular Disease

Volumn 8, Issue 6, 2008, Pages 286-290

  Kuppuswamy, Velmurugan ^a   Mela, Marianna ^b   Eustace, Ian ^c   Gupta, Sandeep ^d  

^a HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^b PAPWORTH HOSPITAL   (United Kingdom)

^c Whipps Cross and St Bartholomews Hospitals ^*

^d Whipps Cross and St Bartholomews Hospitals   (United Kingdom)

Author keywords

Acute coronary syndrome; Atorvastatin; Lipids; National targets

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT;

ACUTE CORONARY SYNDROME; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY CARE UNIT; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENERAL HOSPITAL; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PUBLIC HOSPITAL; SIDE EFFECT; ST SEGMENT ELEVATION; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM; UNSTABLE ANGINA PECTORIS;

EID: 60549114525     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/1474651408097904     Document Type: Article

References (6)

1. Department of Health. National Service Framework for Coronary Heart Disease. London: Crown Copyright, 2000: 16602 http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/ DH_4094275 (Accessed August 2008).
2. Evans PH, Luthra M, Pike C et al. NSF lipid targets in patients with CHD: are they achievable in a real-life primary care setting? Br J Cardiol 2004; 11:71-4.
3. Middleton A, Fuat F. Achieving Lipid Goals in Real Life: The DISCOVERY-UK Study. Br J Cardiol 2006; 13:72-6.
4. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91 (suppl 5):v1-v52.
5. Cooper A, Nherera L, Calvert N et al. Clinical Guidelines and Evidence Review for Lipid Modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners, 2008.
6. Davies A, Hutton J, O'Donnell J et al. Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK. Br J Cardiol 2006; 13:196-202.